| 生物活性 |
CAY10526 is an inhibitor of Y-box binding protein 1 (YB-1) and microsomal prostaglandin E2 synthase 1 (mPGES1) that inhibits PGE2 production by suppressing YB-1 and mPGES1, induces apoptosis, inhibits the JAK/STAT, TGF-β/Smad3, and PI3K/AKT signaling pathways, and can be used for research related to melanoma, prostate cancer, esophageal adenocarcinoma, T-cell lymphoma, and other related conditions. |
体外研究 (In Vitro) |
CAY10526 (5 μM; 1 h) 可强效抑制 NO 供体诱导的 A375 和 SB2 人黑色素瘤细胞中 PGE2 的生成。 CAY10526 (0-20 μM; 72 h) 可强效降低 mPGES1 高表达的人黑色素瘤细胞 A375、SB2 和 WM793 的细胞活力,其 IC50 < 5 μM;而在 mPGES1 低表达的人黑色素瘤细胞 SK-MEL-28、WM1361A 以及 BJ 成纤维细胞中,该化合物的活性显著减弱 (IC50 >10 μM)。 CAY10526 (5 μM; 48 h) 可调控 69 种与细胞死亡及存活相关的蛋白,包括降低 YB-1 磷酸化水平、细胞周期蛋白 B1 以及抗凋亡蛋白 BCL-2/BCL-XL,同时在 A375 和 SB2 人黑色素瘤细胞中上调 p21、促凋亡蛋白 BAX/BAK 以及活化的半胱天冬酶 3。 CAY10526 (1-50 μM; 12 h) 以浓度依赖的方式抑制 DU-145 前列腺癌细胞的增殖,在 10 μM 和 20 μM 浓度下可观察到细胞活力显著降低,且当浓度超过 20 μM 后抑制作用进入平台期。 CAY10526 (10-20 μM; 12 h) 可在体外以浓度依赖的方式下调 DU-145 前列腺癌细胞中 mPGES-1 的表达;在 10 μM 浓度下,相较于完全培养基对照组,它能维持 Beclin-1 的高表达水平,而在 20 μM 浓度下,它可显著降低 mPGES-1 和 Beclin-1 的表达。 CAY10526 (1-50 μM; 18 h) 可强效抑制 OE33 食管腺癌细胞中瘦素诱导的 PGE2 生成,在 10 μM 和 50 μM 浓度下可实现完全抑制。 CAY10526 (10 μM; 18 h) 可抑制 OE33 食管腺癌细胞中瘦素诱导的 mPGES-1 蛋白表达,且不会改变 COX-2 的表达。 CAY10526 (1-50 μM; 24 h) 以浓度依赖的方式抑制 OE33 食管腺癌细胞中瘦素诱导的增殖,在 10 μM 和 50 μM 浓度下达到最大抑制活性,与活性 COX-2 抑制剂浓度的活性相当。 CAY10526 (1-50 μM; 48 h) 以浓度依赖的方式降低血清培养的 OE33 食管腺癌细胞的活细胞数量,在 10 μM 时达到最大活性。 CAY10526 (1-50 μM; 25 h) 可呈浓度依赖性抑制瘦素诱导的 OE33 食管腺癌细胞活细胞数量增加,其最大活性在 10 μM 时达到。 CAY10526 (10 μM;25 h) 可通过作用于 PGE2 产生的上游环节,抑制 OE33 食管腺癌细胞中瘦素诱导的增殖,而外源性 PGE2 可恢复该增殖效应。 CAY10526 (10 μM; 25 h) 可抑制 HUVECs 中 IL-1β 诱导的 PGE2 生成,同时促进 PGI2 生成,且不影响内皮前列环素的合成。 CAY10526 (25 h) 可抑制凝血酶诱导的人脐静脉内皮细胞 (HUVECs) 中 PGE2 的生成,同时促进 PGI2 的生成,且不影响内皮前列环素的合成。 CAY10526 (10-80 μM; 24-72 h) 可抑制人 T 细胞淋巴瘤 Hut78 细胞的增殖,其在 24 h 时的 IC50 为 27.64 μM,且孵育 72 h 后可呈剂量依赖性地抑制细胞活力。 CAY10526 (10-80 μM; 24 h) 可呈剂量依赖性降低人 T 细胞淋巴瘤 Hut78 细胞中 mPGES-1 蛋白的表达,在 24 h 后 40 μM 和 80 μM 浓度下可产生显著抑制作用。 CAY10526 (10-80 μM; 24 h) 可剂量依赖性地抑制人 T 细胞淋巴瘤 Hut78 细胞中 PGE2 的合成,在 24 h 后 10、20、40 和 80 μM 浓度下均表现出显著抑制作用。 CAY10526 (20-40 μM; 24 h) 可剂量依赖性诱导人 T 细胞淋巴瘤 Hut78 细胞凋亡,24 h 后 20 μM 和 40 μM 浓度下的细胞凋亡率均显著升高。 CAY10526 (20-40 μM; 24 h) 可剂量依赖性地上调人 T 细胞淋巴瘤 Hut78 细胞中活化的 caspase-3 表达,24 h 后 20 μM 和 40 μM 浓度下的表达水平均显著升高。 CAY10526 (20-40 μM; 24 h) 可通过降低 JAK1、JAK2 和 p-STAT3 的表达,剂量依赖性地抑制人 T 细胞淋巴瘤 Hut78 细胞中的 JAK/STAT 信号通路;24 h 后,20 μM 和 40 μM 浓度下的抑制作用显著,而总 STAT3 水平保持不变。 CAY10526 (20-40 μM; 24 h) 可通过降低 PI3Kp110、PI3Kp85 及 p-AKT 的表达,剂量依赖性地抑制人 T 细胞淋巴瘤 Hut78 细胞中的 PI3K/AKT 信号通路;作用 24 h 后,20 μM 及 40 μM 浓度下的抑制作用显著,而总 AKT 水平保持不变。 CAY10526 (20-40 μM; 24 h) 可通过降低 TGF-β 和 p-Smad3 的表达,剂量依赖性地抑制人 T 细胞淋巴瘤 Hut78 细胞中的 TGF-β/Smad3 信号通路;作用 24 h 后,20 μM 和 40 μM 浓度下的抑制作用显著,而总 Smad3 水平保持不变。 CAY10526 (20-40 μM; 24 h) 可呈剂量依赖性降低人 T 细胞淋巴瘤 Hut78 细胞中 CyclinD1 的表达,在 24 h 后 20 μM 和 40 μM 浓度下均表现出显著抑制作用。
Cell Viability Assay
| Cell Line: |
A375, SB2, WM793, SK-MEL-28, WM1361A human melanoma cells, BJ normal fibroblasts |
| Concentration: |
0, 1, 5, 10 and 20 μM |
| Incubation Time: |
72 h |
| Result: |
Inhibited cell viability with an IC50 < 5 μM in mPGES1-high melanoma cell lines (A375, SB2, WM793). Showed significantly weaker activity with an IC50 >10 μM in mPGES1-low melanoma cell lines (SK-MEL-28, WM1361A) and normal BJ fibroblasts. |
Cell Proliferation Assay
| Cell Line: |
DU-145 prostate cancer cells |
| Concentration: |
1, 10, 20 and 50 μM |
| Incubation Time: |
12 h |
| Result: |
Inhibited DU-145 cell proliferation in a concentration-dependent manner. Exhibited optical density values of 0.34 at 1 μM, 0.22 at 10 μM, 0.08 at 20 μM, and 0.06 at 50 μM. Reduced cell viability significantly at 10 μM and 20 μM compared to control. Showed no significant difference in cell viability between 20 μM and 50 μM groups. |
Western Blot Analysis
| Cell Line: |
DU-145 prostate cancer cells |
| Concentration: |
10 and 20 μM |
| Incubation Time: |
12 h (serum-free conditions) |
| Result: |
Downregulated mPGES-1 protein expression in a concentration-dependent manner. Reduced Beclin-1 expression at 10 μM compared to serum-free group, while levels remained higher than complete medium control group. Significantly downregulated both mPGES-1 and Beclin-1 at 20 μM. |
ELISA Assay
| Cell Line: |
leptin-stimulated OE33 oesophageal adenocarcinoma cells |
| Concentration: |
1 μM, 10 μM, 50 μM |
| Incubation Time: |
60 min pretreatment, followed by 18 h leptin stimulation |
| Result: |
Caused a concentration-dependent reduction in leptin-driven, COX-2-dependent PGE2 production. Abolished leptin-induced PGE2 production at 10 μM and 50 μM, achieving inhibition comparable to COX-2 inhibitors celecoxib and NS-398 at their active concentrations. |
Western Blot Analysis
| Cell Line: |
leptin-stimulated OE33 oesophageal adenocarcinoma cells |
| Concentration: |
10 μM |
| Incubation Time: |
60 min pretreatment, followed by 18 h leptin stimulation |
| Result: |
Completely blocked leptin-induced mPGES-1 protein expression. Left COX-2 protein expression unaffected. |
Cell Proliferation Assay
| Cell Line: |
leptin-stimulated OE33 oesophageal adenocarcinoma cells |
| Concentration: |
1 μM, 10 μM, 50 μM |
| Incubation Time: |
60 min pretreatment, followed by 24 h leptin stimulation |
| Result: |
Caused a concentration-dependent decrease in leptin-stimulated OE33 cell proliferation. Blocked leptin-induced proliferation at 10 μM and 50 μM with effectiveness matching COX-2 inhibitors celecoxib (1 μM) and NS-398 (10 μM). |
Cell Viability Assay
| Cell Line: |
serum-cultured OE33 oesophageal adenocarcinoma cells |
| Concentration: |
1 μM, 10 μM, 50 μM |
| Incubation Time: |
48 h |
| Result: |
Caused a concentration-dependent reduction in viable OE33 cell numbers, with no further reduction observed at concentrations above 10 μM. Significantly reduced viable cell numbers at all tested concentrations compared to untreated controls. |
Cell Viability Assay
| Cell Line: |
leptin-stimulated OE33 oesophageal adenocarcinoma cells |
| Concentration: |
1 μM, 10 μM, 50 μM |
| Incubation Time: |
60 min pretreatment, followed by 24 h leptin stimulation |
| Result: |
Blunted the leptin-stimulated increase in viable OE33 cell numbers in a concentration-dependent manner, with no additional effect observed at concentrations above 10 μM. Significantly reduced leptin-stimulated viable cell numbers at all tested concentrations compared to leptin-only controls. |
Cell Viability Assay
| Cell Line: |
leptin-stimulated OE33 oesophageal adenocarcinoma cells (PGE2-rescue experiment) |
| Concentration: |
10 μM |
| Incubation Time: |
60 min pretreatment, followed by 24 h stimulation with leptin, PGE2, or leptin + PGE2 |
| Result: |
Allowed exogenous PGE2 to stimulate OE33 cell proliferation even in its presence. Saw the inhibitory effect on leptin-stimulated proliferation reversed by added PGE2. |
ELISA Assay
| Cell Line: |
IL-1β-stimulated human umbilical vein endothelial cells (HUVECs) |
| Concentration: |
10 μM |
| Incubation Time: |
60 min pretreatment, followed by 24 h IL-1β stimulation |
| Result: |
Effectively blocked IL-1β-driven PGE2 production in HUVECs. Significantly enhanced IL-1β-stimulated PGI2 production, unlike COX-2 inhibitors celecoxib and NS-398 which abolished production of both PGE2 and PGI2. |
ELISA Assay
| Cell Line: |
thrombin-stimulated human umbilical vein endothelial cells (HUVECs) |
| Concentration: |
10 μM |
| Incubation Time: |
60 min pretreatment, followed by 24 h thrombin stimulation |
| Result: |
Blocked thrombin-stimulated PGE2 production in HUVECs. Significantly enhanced thrombin-stimulated PGI2 production, unlike COX-2 inhibitors celecoxib and NS-398 which abolished production of both PGE2 and PGI2. |
Western Blot Analysis
| Cell Line: |
human T-cell lymphoma Hut78 cells |
| Concentration: |
10, 20, 40 and 80 μM |
| Incubation Time: |
24 h |
| Result: |
Down-regulated mPGES-1 protein expression in Hut78 cells in a dose-dependent manner. Caused statistically significant reductions at 40 μM and 80 μM compared to untreated cells. |
Apoptosis Analysis
| Cell Line: |
human T-cell lymphoma Hut78 cells |
| Concentration: |
20 and 40 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly increased the apoptosis rate of Hut78 cells in a dose-dependent manner. Caused statistically significant elevations at 20 μM and 40 μM compared to untreated cells. |
Western Blot Analysis
| Cell Line: |
human T-cell lymphoma Hut78 cells |
| Concentration: |
20 and 40 μM
|
| Incubation Time: |
24 h |
...(内容过长已截断)
体内研究 (In Vivo) |
CAY10526 (25-50 mg/kg;腹腔注射;每日一次;连续 15 天) 可使黑色素瘤异种移植瘤体积减小 43%、瘤重降低 48%,同时降低肿瘤组织中 p-YB-1 水平并提高活化型 caspase 3 水平。 CAY10526 (2.5 mg/kg;腹腔注射;每日 1 次;连续 7 天) 无论是在梗阻期间给药还是在梗阻解除时开始给药,均能使 BO 后大鼠的 PGE2 水平恢复正常,并改善或恢复其结肠运动功能及平滑肌收缩功能。
| Animal Model: |
athymic nu/nu (male, 6-8 weeks old, subcutaneous xenograft model) |
| Dosage: |
25 mg/kg; 50 mg/kg |
| Administration: |
i.p.; daily; 15 days |
| Result: |
Reduced tumor volume by 43% and tumor weight by 48% relative to vehicle controls at 50 mg/kg dose. Decreased phosphorylation of Y-box binding protein 1 (p-YB-1) and increased levels of cleaved caspase 3 in tumor tissues at 50 mg/kg dose. |
| Animal Model: |
Sprague-Dawley (male, 225-275 g, partial colon obstruction induced with obstruction band, released after 7 days to create post-bowel obstruction state) |
| Dosage: |
2.5 mg/kg (starting on obstruction release); 2.5 mg/kg (during obstruction period) |
| Administration: |
i.p.; daily; 7 days (starting on obstruction release); i.p.; daily; 7 days (during obstruction period) |
| Result: |
Normalized PGE2 levels in colonic muscularis externae. Eliminated the difference in colon transit geometric center between post-BO and post-sham rats. Restored colonic circular smooth muscle contractility in response to acetylcholine to post-sham levels. Partially but significantly improved colonic circular smooth muscle contractility in response to acetylcholine in the post-BO state. |
|
| 性状 |
固体 |
| 颜色 |
Off-white to yellow |
| 分子量 |
311.16 |
| 分子式 |
C12H7BrO3S |
| CAS No. |
938069-71-7 |
| 体内实验配方 |
10% DMSO+90% Saline: 1.5 mg/mL (4.82 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 |
| 储存方式 |
4°C, sealed storage, away from moisture and light
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
溶液配制表
|
DMSO 中的溶解度 : 66.67 mg/mL (214.26 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO) | 可选溶剂 | 浓度 | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| DMSO | 1 mM | 3.2138 mL | 16.0689 mL | 32.1378 mL | 80.3445 mL | | 5 mM | 0.6428 mL | 3.2138 mL | 6.4276 mL | 16.0689 mL | | 10 mM | 0.3214 mL | 1.6069 mL | 3.2138 mL | 8.0345 mL | | 15 mM | 0.2143 mL | 1.0713 mL | 2.1425 mL | 5.3563 mL | | 20 mM | 0.1607 mL | 0.8034 mL | 1.6069 mL | 4.0172 mL | | 25 mM | 0.1286 mL | 0.6428 mL | 1.2855 mL | 3.2138 mL | | 30 mM | 0.1071 mL | 0.5356 mL | 1.0713 mL | 2.6782 mL | | 40 mM | 0.0803 mL | 0.4017 mL | 0.8034 mL | 2.0086 mL | | 50 mM | 0.0643 mL | 0.3214 mL | 0.6428 mL | 1.6069 mL | | 60 mM | 0.0536 mL | 0.2678 mL | 0.5356 mL | 1.3391 mL | | 80 mM | 0.0402 mL | 0.2009 mL | 0.4017 mL | 1.0043 mL | | 100 mM | 0.0321 mL | 0.1607 mL | 0.3214 mL | 0.8034 mL |
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|